| Autor: |
Morrell ED; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., O'Mahony DS; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., Glavan BJ; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., Harju-Baker S; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., Nguyen C; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., Gunderson S; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., Abrahamson A; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., Radella F 2nd; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., Rona G; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and., Black RA; 2 Biomedical Informatics Core of the Institute of Translational Health Sciences, University of Washington, Seattle, Washington., Wurfel MM; 1 Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington; and. |
| Abstrakt: |
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) regulates numerous intracellular signaling pathways involved in inflammation and apoptosis. We hypothesized that genetic variation in MAP3K1 might be associated with outcomes in patients with acute respiratory distress syndrome (ARDS), and that these variants would alter MAP3K1-mediated changes in inflammation and transcriptional regulation. To test this hypothesis, we genotyped single-nucleotide polymorphisms covering linkage disequilibrium bins in MAP3K1 in 306 subjects with ARDS from the ARDSNet FACTT (Fluid and Catheter Treatment Trial) study, and tested for associations between MAP3K1 single-nucleotide polymorphisms and ventilator-free days (VFDs) and mortality. We then validated these associations in a separate cohort of 241 patients with ARDS from Harborview Medical Center (Seattle, WA). We found the variant allele of rs832582 (MAP3K1 906Val ) was significantly associated with decreased VFDs using multivariate linear regression (-6.1 d, false discovery rate = 0.06) in the FACTT cohort. In the Harborview Medical Center cohort, subjects homozygous for MAP3K1 906Val also had decreased VFDs (-15.1 d, false discovery rate < 0.01), and increased 28-day mortality (all subjects homozygous for the rare allele died). In whole blood stimulated with various innate immune agonists ex vivo, MAP3K1 906Val was associated with increased IL-1β, IL-6, IL-8, monocyte chemoattractant protein 1, and TNF-α production. Transcriptome analysis of whole blood stimulated with Toll-like receptor 4 agonist ex vivo demonstrated enrichment of inflammatory gene sets in subjects homozygous for MAP3K1 906Val . Our findings show a robust association between the variant allele of rs832582 (MAP3K1 906Val ) and decreased VFDs in patients with ARDS and suggest that this variant may predispose individuals to a greater inflammatory response. |
